Nicholas D Mitchell1, G B Baker. 1. Department of Psychiatry, University of Alberta Hospital, Edmonton, AB, Canada. ndm@ualberta.ca
Abstract
OBJECTIVE: To review the literature on the involvement of glutamate (Glu), including its interactions with other neurochemical systems, in the pathophysiology of depression. METHOD: A MEDLINE search using the terms glutamate, depression and major depressive disorder, was performed. RESULTS: Alterations in proteins involved in glutamatergic signalling are implicated in variations in behaviour in animal models of depression. Drugs acting at Glu receptors appear to have antidepressant-like effects in these models, and traditional antidepressant pharmacotherapies act on the glutamatergic system. Recent evidence from genetic studies and in vivo spectroscopy also correlate glutamatergic dysfunction with depression. Trials of N-methyl-d-aspartate receptor antagonists in humans have provided mixed results. CONCLUSION: A growing body of evidence indicates that the glutamatergic system is involved in the pathophysiology of depression, and may represent a target for intervention.
OBJECTIVE: To review the literature on the involvement of glutamate (Glu), including its interactions with other neurochemical systems, in the pathophysiology of depression. METHOD: A MEDLINE search using the terms glutamate, depression and major depressive disorder, was performed. RESULTS: Alterations in proteins involved in glutamatergic signalling are implicated in variations in behaviour in animal models of depression. Drugs acting at Glu receptors appear to have antidepressant-like effects in these models, and traditional antidepressant pharmacotherapies act on the glutamatergic system. Recent evidence from genetic studies and in vivo spectroscopy also correlate glutamatergic dysfunction with depression. Trials of N-methyl-d-aspartate receptor antagonists in humans have provided mixed results. CONCLUSION: A growing body of evidence indicates that the glutamatergic system is involved in the pathophysiology of depression, and may represent a target for intervention.
Authors: Siddheshwar Utge; Erkki Kronholm; Timo Partonen; Pia Soronen; Hanna M Ollila; Anu Loukola; Markus Perola; Veikko Salomaa; Tarja Porkka-Heiskanen; Tiina Paunio Journal: Sleep Date: 2011-10-01 Impact factor: 5.849
Authors: Kevin N Hascup; Erin R Hascup; Michelle L Stephens; Paul E A Glaser; Takashi Yoshitake; Aleksander A Mathé; Greg A Gerhardt; Jan Kehr Journal: Neuropsychopharmacology Date: 2011-04-27 Impact factor: 7.853
Authors: Gabriel Oh; Sun-Chong Wang; Mrinal Pal; Zheng Fei Chen; Tarang Khare; Mamoru Tochigi; Catherine Ng; Yeqing A Yang; Andrew Kwan; Zachary A Kaminsky; Jonathan Mill; Cerisse Gunasinghe; Jennifer L Tackett; Irving I Gottesman; Gonneke Willemsen; Eco J C de Geus; Jacqueline M Vink; P Eline Slagboom; Naomi R Wray; Andrew C Heath; Grant W Montgomery; Gustavo Turecki; Nicholas G Martin; Dorret I Boomsma; Peter McGuffin; Rafal Kustra; Art Petronis Journal: Biol Psychiatry Date: 2014-07-01 Impact factor: 13.382